Citadel Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $184K | Buy |
+14,600
| New | +$196K | ﹤0.01% | 11489 |
|
|
2025
Q4 | – | Sell |
-12,000
| Closed | -$144K | – | 12984 |
|
|
2025
Q3 | $144K | Buy |
+12,000
| New | +$95.9K | ﹤0.01% | 11562 |
|
|
2025
Q2 | – | Sell |
-13,900
| Closed | -$76.7K | – | 13176 |
|
|
2025
Q1 | $76.7K | Buy |
13,900
+1,500
| +12% | +$9.27K | ﹤0.01% | 11811 |
|
|
2024
Q4 | $71.3K | Buy |
12,400
+7,800
| +170% | +$74.8K | ﹤0.01% | 11935 |
|
|
2024
Q3 | $47.7K | Buy |
4,600
+2,300
| +100% | +$30.1K | ﹤0.01% | 11964 |
|
|
2024
Q2 | $29.8K | Sell |
2,300
-1,000
| -30% | -$13.5K | ﹤0.01% | 12278 |
|
|
2024
Q1 | $57.6K | Sell |
3,300
-300
| -8% | -$3.97K | ﹤0.01% | 12039 |
|
|
2023
Q4 | $33.9K | Buy |
3,600
+2,100
| +140% | +$19.6K | ﹤0.01% | 12161 |
|
|
2023
Q3 | $16.8K | Buy |
1,500
+600
| +67% | +$9.66K | ﹤0.01% | 12765 |
|
|
2023
Q2 | $19.3K | Sell |
900
-800
| -47% | -$23.6K | ﹤0.01% | 12756 |
|
|
2023
Q1 | $68.7K | Sell |
1,700
-1,800
| -51% | -$86K | ﹤0.01% | 11766 |
|
|
2022
Q4 | $163K | Sell |
3,500
-12,900
| -79% | -$588K | ﹤0.01% | 10481 |
|
|
2022
Q3 | $851K | Buy |
+16,400
| New | +$958K | ﹤0.01% | 7345 |
|
|
2022
Q1 | – | Sell |
-12,700
| Closed | -$950K | – | 13820 |
|
|
2021
Q4 | $950K | Buy |
+12,700
| New | +$997K | ﹤0.01% | 8102 |
|
|
2021
Q3 | – | Sell |
-56,400
| Closed | -$2.48M | – | 13975 |
|
|
2021
Q2 | $2.48M | Sell |
56,400
-10,900
| -16% | -$534K | ﹤0.01% | 6064 |
|
|
2021
Q1 | $3.32M | Buy |
67,300
+26,600
| +65% | +$1.33M | ﹤0.01% | 5200 |
|
|
2020
Q4 | $1.71M | Buy |
+40,700
| New | +$1.79M | ﹤0.01% | 5685 |
|
|
2020
Q2 | – | Sell |
-31,500
| Closed | -$1.62M | – | 9941 |
|
|
2020
Q1 | $1.62M | Sell |
31,500
-3,100
| -9% | -$165K | ﹤0.01% | 4488 |
|
|
2019
Q4 | $2.14M | Buy |
34,600
+28,300
| +449% | +$1.75M | ﹤0.01% | 4309 |
|
|
2019
Q3 | $379K | Sell |
6,300
-19,700
| -76% | -$1.46M | ﹤0.01% | 7215 |
|
|
2019
Q2 | $2.19M | Buy |
26,000
+14,900
| +134% | +$1.34M | ﹤0.01% | 4360 |
|
|
2019
Q1 | $1.06M | Buy |
11,100
+2,000
| +22% | +$179K | ﹤0.01% | 5478 |
|
|
2018
Q4 | $645K | Sell |
9,100
-10,700
| -54% | -$820K | ﹤0.01% | 6002 |
|
|
2018
Q3 | $1.69M | Buy |
19,800
+13,400
| +209% | +$1.34M | ﹤0.01% | 4670 |
|
|
2018
Q2 | $742K | Buy |
+6,400
| New | +$639K | ﹤0.01% | 5728 |
|
|
2017
Q3 | – | Sell |
-8,100
| Closed | -$291K | – | 7631 |
|
|
2017
Q2 | $291K | Sell |
8,100
-9,400
| -54% | -$301K | ﹤0.01% | 5963 |
|
|
2017
Q1 | $539K | Buy |
+17,500
| New | +$545K | ﹤0.01% | 4894 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Citadel Advisors's ENTA Position: Q1 2026 in Review
Citadel Advisors increased its Enanta Pharmaceuticals (ENTA) stake by 182% in Q1 2026, buying an estimated $2.27M and bringing the position to 262,533 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #5069.
Citadel Advisors first reported a position in ENTA in Q4 2013 and has held it in 40 quarters since. The position peaked at $23.9M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Citadel Advisors held 262,533 shares of Enanta Pharmaceuticals worth $3.32M as of Q1 2026.
- Citadel Advisors bought 169,375 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.27M.
- Enanta Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5069 holding.
- Citadel Advisors first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 40 quarters since.
- Citadel Advisors's Enanta Pharmaceuticals position peaked at $23.9M in Q1 2019.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.